BiotechTube
Home/Pipeline/docirbrutinib (AS-1763)

docirbrutinib (AS-1763)

B-cell malignancies

Phase 1bActive

Key Facts

Indication
B-cell malignancies
Phase
Phase 1b
Status
Active
Company
Carna Biosciences

About Carna Biosciences

Carna Biosciences is a dual-strategy Japanese biotech with a core focus on developing proprietary kinase inhibitors for oncology and hematology, while also generating revenue through a portfolio of kinase-focused research products and discovery services. Its lead clinical assets include docirbrutinib, a next-generation BTK inhibitor for B-cell malignancies, and monzosertib, a preclinical compound. The company is publicly traded, leveraging its deep kinase expertise to build a pipeline and support external R&D efforts.

View full company profile

Therapeutic Areas

OncologyHematology

Other B-cell malignancies Drugs

DrugCompanyPhase
BI-1607BioInvent InternationalPreclinical/Phase 1
BAFFR Allo CAR-NK CellsPeproMene BioPre-clinical
IKS03Iksuda TherapeuticsClinical
TNB-486Ancora BioPhase 1
P-CD19CD20-ALLO1Poseida TherapeuticsPhase 1
Kymriah® (tisagenlecleucel)NovartisApproved
KITE-363Gilead SciencesPhase 1/2
HSK29116Haisco Pharmaceutical GroupPhase I/II
TG-1701TG TherapeuticsPhase 1
TG-1801TG TherapeuticsPhase 1
REC-3565Recursion PharmaceuticalsPhase 1
Plamotamab (XmAb®13676)XencorPhase 2